Objective: To evaluate the mid-term results of endovascular stent-grafting for type B aortic dissection, in comparison with those of standard medical therapy in uncomplicated cases. Methods: Between January 1999 and 2004, among 56 patients (mean age 59.5G11.5 years) with type B aortic dissection, hypotensive medical therapy was the only treatment in 28 uncomplicated cases, (group A), while stent-graft implantation was performed in 28 patients with uncontrolled hypertension, persistent pain or evidence of dissection progression or complication (group B). In 14 cases (50%) the procedure was performed in an acute setting. Stent-grafting procedures were monitored with intraoperative transesophageal echocardiography and cine-angiography. CT scan and trans-esophageal echocardiography were performed before hospital discharge, at 6 and 12 months and then yearly. Results: Follow-up (range 1-61 months, average 18.1G16.9 months) was 100% complete. In-hospital mortality was 10.7% (three patients, all belonging to Group B; PZ0.24). No spinal cord injuries were observed. Early endoleak occurred in one patient (3.5%). Mid-term mortality was lower in Group B, although the difference was not significant (10.7 versus 14.3% in Group A, PZ0.71). Follow-up CT scans evidenced complete thrombosis of the false lumen in 75% cases in Group B, 10.7% in Group A (PZ0.0001), and an aneurismal dilatation of the descending aorta in 3.5% cases in Group B, 28.5% in Group A (PZ0.02). Conclusions: Although with still considerable early mortality, endovascular stent-graft implantation is an effective option for the treatment of complicated type B aortic dissection. Endovascular treatment achieved a better mid-term fate of the descending thoracic aorta than medical therapy alone, even in patients with worse preoperative conditions. Q
Introduction
Aortic dissection originating after the left subclavian artery and extending into the descending aorta, also known as Stanford type-B dissection (TBD), remains a therapeutic dilemma. Surgical management still represents a valid option in spite of the dramatic improvement in operative techniques and in methods of spinal protection. However, postoperative mortality remains high, ranging in published series from 6 to 67% [1, 2] . Thereby, medical therapy is indicated in case of uncomplicated TBD, and yields an early mortality rate of 10%, a 1-year mortality of 20% and a need for surgical operation during the long-term follow-up reaching 20% [3, 4] . Both mortality and aortic events requiring operation are thought to be related to scarce response to hypotensive therapy, a condition clinically associated to aortic dissection itself [5] . Endovascular stent-graft (EVG) implantation is the most recently introduced therapeutic approach and it has been gaining space in this field thanks to its less-invasive nature when compared to surgery, and after the demonstration in the first series [6] [7] [8] [9] of a high incidence of false lumen late thrombosis. Patency of false lumen is known to represent a risk factor for dissection-related death or adverse events in patients surviving the acute phase of TBD, whereas the thrombotic obliteration of the false lumen is associated with better long-term outcomes [10] .
The aim of the present retrospective study was to evaluate the results of medical therapy and, in comparison, those of EVG therapy, in terms of persistence or thrombosis of the false lumen as well as aneurysm development.
Materials and methods

Study design
This is a retrospective study analysing the experience over 5 years in the treatment of TBD. From January 1999 and 2004, a total of 64 patients were referred to the Department of Cardio-Thoracic Sciences, Second University of Naples, 'V. Monaldi' Hospital, for acute type B aortic dissection. Unless a complication had already occurred (eight patients, who underwent urgent surgical treatment), all 64 patients were initially treated by mean of intravenous b-blockers, urapidil and/or nitroprusside until stable pressure control was reached and then with oral medical therapy with betablockers, ACE-I, and CaCC-antagonists. Twenty-eight patients were discharged in stable conditions: they did not experience complications and none of them underwent EVG implantation during the follow-up (those patients have been considered retrospectively as 'group A' in the present study). In other 28 patients (considered as 'group B') EVG implantation was needed either in the acute phase (14 patients) or after unsuccessful domiciliary medical therapy during the follow-up. The main indications included: pain persistence in spite of medical therapy in five patients, signs of distal hypoperfusion in 10 (lower limb ischemia in 4, lower limb ischemia and anuria in 4, lower limb and bowel ischemia in 1, anuria in 1), initial signs of aortic rupture in 9, progression of aneurismal dilation of the descending aorta during the follow-up (defined as a diameter R5 cm and/or annual growth rate R0.4 cm/year [11] ) in four. EVG implantation was technically feasible in all those patients. All patients treated with EVG implantation were studied by preoperative CT-scan and trans-esophageal echocardiography (TEE). Thus, the present study overall included 56 patients of both sexes (47 males and 9 females), between 34 and 76 years of age (mean age 59.5G11.5 years). Baseline data of the two groups are reported in Table 1 .
EVG procedure
The procedures were always performed in the operative room under general anaesthesia and controlled hypotension (mean arterial pressure of 70 mmHg), or in the angiography suite with the cardiac surgery operative room on stand-by. The common femoral artery was surgically exposed and controlled proximally and distally. If the femoral artery appeared inadequate, the iliac artery was used for vascular access. One hundred IU/kg of unfractionated heparin were administered intravenously in each case. According to vascular anatomy, a percutaneous left and/or right brachial artery approach was selected, allowing a catheter to be inserted over a guide wire to localize the subclavian artery and to be used for aortograms.
Two different stent graft devices were used: Talente (Medtronic, World Medical Manufacturing Corp, Sunrise, FL) in 19 patients and Excluder w (Gore, Sunnyvale, CA) in nine patients. Once the stent graft was released, an arteriogram was performed to verify the complete closure of the proximal intimal tear and the absence of peri-graft leakage. In all cases, intra-operative transesophageal color-Doppler echocardiography was performed to identify the site of intimal tear for correct EVG positioning and to verify the success of the procedure.
Follow-up
All patients have been followed-up by our laboratory of echocardiography before discharge, at 6 and 12 months after hospital discharge and then, in the absence of complications, yearly. At every follow-up visit the patient's history was updated, arterial pressure controlled at each arm and TEE was performed. At TEE, descending thoracic aorta diameter was measured and the possible presence of intimal tears sought for; flow characteristics in the true and false lumen were investigated. The expansion rate of the descending aorta was calculated as the difference between the current diameter and the last follow-up measurement divided by the time interval between the two examinations. In group B patients graft position was checked and possible endoleaks searched for. When quality of TEE images was unsatisfactory, further information was needed, or the procedure was not tolerated or refused by the patient, 3-mm section spiral angio-TC scan with longitudinal reconstructions was performed. Early mortality and morbidity included events occurring within 30 days of treatment (EVG positioning in group B; beginning of medical therapy in group A), either in hospital or after discharge. Information about patients was obtained both from retrospective chart review and by contacting patients or their treating physicians. The follow-up was 100% complete.
Statistical analysis
Continuous variables were expressed as meansGSD and were compared by the Student's t test. Differences between the groups in categorical variables were analyzed by the c 2 test or Fisher's exact test. Actuarial survivals (Kaplan-Meyer method) were compared with the log-rank test. All P values were two-tailed, and a P value of less than 0.05 was considered to indicate statistical significance.
Results
Operative outcomes
In group B, EVG procedure was successfully carried out in 100% of cases. In three cases (10.7%) the site of sealing was too close to the left subclavian artery origin to spare it and the exclusion of the artery was necessary, requiring subsequent carotid-subclavian by-pass. In five cases (17.8%) multiple graft implantation was required in a 'telescope' fashion. Total graft length averaged 153.2G 28.9 cm, ranging from 102 to 270 cm. All patients who underwent medical treatment were discharged in overall good conditions within 7 days of admission.
Early results
In no case postoperative paraplegia occurred. No hospital (30-days) death was observed in group A. Thirty-days mortality in Group B was 10.7% (PZ0.24): all three patients died within 24 h of procedure. Two of them had undergone EVG implantation for complicated chronic dissection, both with a Talent type graft prosthesis. In the first patient, a new tear developed at the site of EVG proximal sealing soon after deployment, generating retrograde dissection: a second, more proximal stent was implanted, occluding the origin of the subclavian artery and requiring subsequent carotidsubclavian by-pass: the patient never awoke and died on the 27th post-operative day. Hemorrhagic shock due to aortic rupture occurred while positioning a second stent for false lumen persistence after first EVG implantation in the other patient with complicated chronic dissection. Both those patients had signs of particularly severe atherosclerosis of the aortic wall at TEE and CT scan. In the third patient, who had developed hemorrhagic shock few hours after admission, the procedure was performed in the acute phase, using an Excluder EVG model and easily managing to obliterate the false lumen: nevertheless, multiorgan failure, including hepatic, renal and respiratory failure, caused death 12 h after the procedure.
Late results
Optimal pressure control with hypotensive therapy was found during the follow-up in only 11 patients from group A and 13 from group B. Mean follow-up time was 18.1G16.9 months (range 1-61 months): it reached 19.4G13.2 months in group A, 17.5G13.0 in group B (PZNS). Among group A patients, 4 (14.3%) died during the follow-up. In one of them the cause of death was acute aortic rupture (aortic diameter at the last control was 5.6 cm: the patient, who had several co-morbidities, including chronic pulmonary disease, diabetes and coronary artery disease, did not give his consent to invasive treatment), in 1 acute myocardial infarction, in two sudden death. In this group 1, 3 and 5 years survival, considering both in-hospital and follow-up deaths, was 90.8, 84.3, 84.3% versus 86.3, 86.3 and 86.3% in group B (PZ0.71) (Fig. 1) . In no patients from group B an endoleak was evidenced in the follow-up time. Only in one patient the persistence of the false lumen at CT scan suggested the presence of an endoleak; however, an accurate TEE evaluation revealed that the flow in the false lumen was due to the persistence of an intimal tear proximally to the sealing site. The patient underwent a new EVG implantation successfully.
A complete obliteration of the false lumen was observed in three out of the 28 group A patients and in 18 of the 25 survivors from group B (10.7 versus 72%; P!0.001) (Fig. 2) . In three group B patients, there was a persistence of flow in the false lumen and distal tears were detected: in one patient the tear was already present at the time of EVG implantation and had not been treated since too close to the celiac tripod, while in the other two, the tears were new findings, being absent at the previous follow-up control. The analysis of the aortic diameters in the follow-up showed a significantly lower expansion rate in group B (0.15 versus 0.32 cm/year in group A; PZ0.02). The finding of a new aneurismal dilatation in the follow-up was registered in one patient from group B, who had a tear distally to the EVG stent, while it was noticed in six patients belonging to group A (21.4%; PZ0.04); in those patients with aortic dilation in the follow-up, the mean diameter at the last control was 4.82G0.37 (range: 4.5-5.5); in no patient, except for one who has undergone surgical treatment at another Institution, the indication to treatment was posed, since the aortic dilatation had not reached 5 cm.
Discussion
As a recently introduced technique, EVG implantation for TBD of the aorta is currently recommended for complicated cases [11] , as an alternative to the surgical method, and short-and mid-term studies performed so far have claimed encouraging results [6, 8, 12] .
The present study confirmed the efficacy of EVG in the mid-term follow-up, with an overall survival at 5 years of 89.3%, which is comparable to that reported in recent studies [7, 13] ; all deaths notably occurred in the periprocedural phase, indicating that maybe a more appropriate 
patient selection, i.e. indications to EVG more accurately restricted to 'safer' anatomical situations, could have lead to better results. Moreover when looking at our mortality rate one should also consider that it includes the learningcurve period of our experience with EVG in the clinical setting of aortic dissection.
It is well-known that the appearance of complications in patients with TBD dramatically worsens the natural history of the disease and mandates intervention. From this point of view, due to the retrospective nature of this study, the reported outcomes must be viewed at as the results of two different approaches, both applied according to the currently accepted guidelines [11] , in two groups of patients characterised by profound clinical heterogeneity. Early mortality in group B (10.7%) was considerable: however, this result should be analysed in the light of the fact that 50% of EVG implantations were carried out in patients in whom acute complications had developed early (during first hospital admission). Although no analysis of risk factors for peri-procedural death could be performed due to the low numbers of this study, severe atherosclerotic degeneration of the aortic wall and, obviously, worse general conditions (preoperative hemorrhagic shock) seemed associated with the risk of lethal peri-procedural complications. In the other 50% patients, endoluminal treatment was performed after domiciliary medical therapy alone had failed preventing the progression of the disease. The evidence of a 5-year survival in group B patients being numerically comparable to that in group A suggests that EVG implantation can make the midterm prognosis of complicated TBD quite similar to that of uncomplicated TBD treated with hypotensive therapy alone, suggesting a possible absolute advantage of EVG over medical treatment. Only prospective randomized studies could assess the superiority of EVG to medical therapy when applied in the same clinical setting (for ethical reasons it should be the uncomplicated TBD). The ongoing INSTEAD trial will certainly add important information to the debate about the possibility to extend the current indications to EVG for aortic TBD.
Once EVG has been performed successfully it seems to favourably change the natural history of the disease, as documented by the low growth rate registered in the followup of the present study as well as the low incidence of aneurismal dilation, which was 4%, consistently with the reports by Dake et al. [7] (one patient with a distal tear). In 72% of EVG patients, a complete thrombosis of the false lumen was seen, a phenomenon that is known to enhance the process of aortic remodelling with gradual true lumen expansion and obliteration of the false lumen [6] . It has been found that aortic-related deaths and events in the follow-up significantly decrease, if complete thrombosis of the false lumen has been achieved [10, 14] . The rate of persistence of flow in the false lumen in the present series could be even considered surprisingly low in a cohort of patients including such a high number of non-responders to medical therapy, as shown by the percentages of patients with unsatisfactory blood pressure control. A better understanding of the relation between scarce response to medical therapy and false lumen patency should be obtained in order to possibly expand the indications of EVG to include selected patients without acute complications but likely more prone to worse long-term outcomes.
Study limitations
As already stated above, the two groups compared in this study were remarkably different as to pre-treatment conditions. This bias was inevitable for a retrospective comparison, considering the current guidelines for indication to EVG in patients with TBD. However, the aim of the analysis was to assess how EVG can modify the fate of the descending aorta in terms of false lumen obliteration and prevention of aneurismal dilatation, and the only possible setting to compare was medically treated TBD.
Conclusions
Endovascular repair for complicated type B aortic dissection is a feasible option for the treatment of complicated TBD. Peri-procedural mortality can be considerable, although lower than reported in some surgical series, but studies on EVG in the setting of uncomplicated TBD, that are so far lacking, could change this evidence. The endoluminal treatment resulted in a significant larger percentage of post-operative thrombosis of the false lumen compared to medical treatment. Aneurismal dilation of the aorta following EVG repair seems to be rare and this may represent an advantage over conservative treatment.
